Act early, be paranoid: how the ceo of a medical research company tackled covid-19 by DiCarlo, Renzo
Act	early,	be	paranoid:	how	the	CEO	of	a	medical
research	company	tackled	COVID-19
For	the	CEO	of	a	medical	research	company,	COVID-19	presents	particular	challenges.	LSE	alumnus	Renzo
DiCarlo	describes	how	his	medical	research	company	decided	early	on	to	focus	on	control	and	prevention	of	the
virus,	rather	than	detection	and	tracing.	
It	is	now	nine	months	since	I	began	working	with	clients	in	Wuhan,	China	who	were	worried	about	a	rapidly-
spreading	new	virus.	BioPharma	Services	(BPSI)	is	a	medical	research	company	that	carries	out	Phase	1	drug
development	on	many	treatments,	including	COVID-19	therapeutics.	This	put	us	in	an	extraordinary	position	during
the	pandemic.
My	advice	to	peers,	colleagues	and	leaders	in	industry	is	never	to	take	anything	for	granted	in	this	new	normal.	A
degree	of	paranoia	has	not	only	enabled	us	to	survive	but	to	develop	new	solutions.	Business	leaders	need	to
anticipate	infection	risks,	check	biological	data	and	act	early.
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Anticipating	risks	means	analysing	the	marketplace,	community,	and	your	company	to	put	in	solutions	that	are
ahead	of	the	economic	and	pandemic	curve.	For	example,	it	was	clear	in	January	from	initial	spread	data	in	Wuhan
that	the	R0	(transmission	value)	of	COVID-19	was	significantly	higher	than	the	flu	virus,	which	has	an	R0	of	between
0.8	and	1.8.	With	an	R0	of	2.5	to	4,	COVID-19’s	ability	to	spread	is	two	to	three	times	higher	than	the	flu.
In	February	2020,	we	convened	a	COVID	governance	meeting	at	our	company	to	discuss	ways	to	keep	our	staff,
patients,	and	community	safe	while	still	conducting	much-needed	clinical	research	trials.	This	governance
committee	was	made	up	of	scientists,	MDs	and	business	executives,		who	met	weekly.	The	resulting	policies
allowed	us	to	stay	open	and	flourish	by	focusing	on	preventative	and	control	measures,	rather	than	detection	and
tracing.	Our	doctors	had	worked	on	SARS-Ver	1	in	the	early	2000s,	which	gave	us	with	insights	not	readily
available	in	the	marketplace.
We	took	the	decision	to	focus	on	monitoring	biological	metrics	and	implementing	a	100%	mask	policy	within	our
facilities.	This	decision	was	taken	months	in	advance	of	any	public	health	mandates	to	wear	masks.	Our	site	is
safer	than	a	hospital,	and	we	are	not	overloading	the	public	health	system	with	non-critical	PCR	COVID	testing.
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Unfortunately,	other	North	American	companies	who	focused	on	testing	rather	than	prevention	of	spread	were
forced	to	shut	down	periodically,	deep	clean	often	and	quarantine	large	numbers	of	staff	due	to	super-spreading
scenarios.	These	could	have	been	prevented	by	controlling	the	spread	within	their	facility,	rather	than	trying	to
detect	infected	individuals.
I	recommend	that	leaders	and	people	check	and	verify	all	biological	data	in	this	new	reality.	The	data	being
provided	by	institutions,	companies	and	government	needs	to	be	verified,	and	triple-checked.	At	the	end	of	March,
one	of	our	employees	had	developed	COVID	symptoms	four	days	after	their	last	shift.	We	got	the	public	health
result	showing	our	employee	was	indeed	positive	one	week	after	this	initial	notification.	Proper	procedures	were
followed	to	verify	that	the	person	was	always	wearing	a	mask	during	her	last	shift,	no	one	had	encountered	her
during	her	time	at	work,	and	the	facility	had	been	deep	cleaned	two	days	after	her	last	shift.	(The	definition	of
‘encounter’	as	per	our	procedures	is	no	one	coming	within	two	metres	of	the	employee	during	her	work	shift.)	Our
main	concern	in	this	case	–	for	the	employee	and	our	staff	–	was	determining	when	it	would	be	safe	for	her	to	return
to	work.	Public	Health	had	told	us	we	should	quarantine	her	at	home	for	two	weeks,	which	was	consistent	with	our
COVID	Positive	Response	Plan	(PRP).	They	stated	that	the	employee	could	return	to	work	after	two	weeks	if
symptoms	had	been	resolved,	with	no	need	for	a	new	COVID	PCR	test.
Due	to	the	sensitivity	of	our	clinical	trials,	we	had	mandated	testing	requirements	above	the	public	health	minimum
which	required	additional	testing,	and	specifically	two	negative	results	in	a	row	prior	to	returning	to	work.	The
employee,	being	a	medical	professional,	complied	with	these	additional	requirements.	We	received	a	negative
result	for	the	first	test	but	a	positive	on	the	subsequent	test	one	week	after.	In	the	early	days,	it	was	hard	to
determine	if	the	person	had	been	reinfected,	if	test	error	had	occurred,	or	if	a	proper	sample	was	obtained.	Even
now,	central	laboratories	admit	that	current	testing	has	a	large	margin	of	error,	requiring	that	you	always	test,	re-test
and	verify	data.	Due	to	the	hypersensitivity	of	the	community	and	our	staff,	we	took	nothing	for	granted	and	asked
the	now	asymptomatic	employee	to	re-quarantine	for	another	two	weeks	and	redo	the	double	tests.	We	eventually
got	the	two	negative	tests	in	a	row	and	the	employee	is	safe	and	back	at	work.
More	importantly,	this	one	incident	did	not	cause	a	major	spread	in	our	facility	and	avoided	the	need	for	a	full
shutdown	of	the	site.	This	experience	taught	us	to	stay	vigilant,	manage	fears	and	verify	the	data.	By	being	so
rigorous	and	demonstrating	this	to	our	clients	and	staff,	they	feel	safer	at	BioPharma	than	most	community
hospitals.
Being	proactive	has	proved	vital.	Developing	a	PRP	early	on	allowed	us	to	perfect	it	in	real	time	with	active	COVID
cases.	The	original	PRP	was	developed	by	mapping	out	and	creating	theoretical	“what	if”	scenarios,	should
someone	should	test	positive	for	COVID.	The	PRP	that	exists	today	is	infinitely	better	and	more	nuanced	than	the
untested	version	in	March	2020.	The	reasons	for	its	success	are	policies	centered	around	time,	distance,	and
barriers	to	minimise	spread.
In	May,	an	employee	confirmed	that	her	mother,	whom	she	lived	with,	had	tested	positive	for	COVID.	As	per	our
PRP,	we	isolated	our	employee	for	two	weeks	and	asked	for	the	double	negative	test	before	returning	to	work.
Because	both	mother	and	daughter	were	trained	medical	professionals,	they	used	time,	distancing,	and	barrier
techniques	to	minimise	contamination	between	each	other.	The	mother’s	symptoms	resolved,	and	she	eventually
tested	negative.	To	our	pleasant	surprise,	our	employee	never	became	COVID	positive	even	though	she	lived	with
her.	Masks,	isolation	and	staying	two	metres	apart	proved	to	be	quite	effective,	even	for	two	individuals	living	in	the
same	household.	This	taught	us	early	on	that	good	safety	practices	and	procedures	go	a	long	way	to	minimising	the
spread.	With	the	data	from	this	case,	PRP	specifics	were	updated	to	make	it	more	robust	and	relevant.	We	continue
to	be	vigilant	and	proactive	by	continuously	improving	our	PRP	with	real	data	as	cases	continue	to	arise,	as	testing
quality	evolves,	and	safety	guidelines	improve.
Lastly,	business	leaders	need	to	act	early,	even	if	not	all	the	data	is	present.	BPSI	volunteered	and	donated	its
Research	&	Development	clinic	for	COVID	research	in	February	2020,	when	the	virus	was	not	considered	a	threat
to	more	developed	countries	and	had	not	yet	been	declared	a	pandemic.	This	resulted	in	numerous	unsolicited
requests	in	the	following	months	for	help	with	coronavirus	therapeutic	drug	development,	using	our	assets	and
expertise.
This	post	represents	the	views	of	the	author	and	not	those	of	the	COVID-19	blog,	nor	LSE.
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